The Breakthrough and the Bill

On Sunday 31 May, in front of an audience of oncologists at the American Society of Clinical Oncology's annual meeting in Chicago, a Californian biotechnology company named Revolution Medicines presented Phase 3 trial results for an experimental pill called daraxonrasib. The drug had been tested against standard chemotherapy in five hundred patients with advanced pancreatic cancer whose disease had progressed despite earlier treatment. Patients on the pill lived a median of 13.2 months. Patients on chemotherapy lived 6.7. The risk of death was reduced by sixty percent. It is the first drug ever to push median survival past one year in a Phase 3 pancreatic cancer trial, in any line of therapy. The findings were published the same day in The New England Journal of Medicine. They are real, and they matter. What follows is also real, and it also matters.

I. What the drug does

Pancreatic cancer kills roughly fifty-two thousand Americans every year and the great majority of the sixty-seven thousand newly diagnosed. The five-year survival rate has long sat in single digits. For decades, drug development against the disease has been a sequence of expensive failures. Roughly nine in ten pancreatic cancers carry a mutation in a gene called KRAS, a gene that regulates cell growth and which, when broken, drives the tumour. KRAS was for years considered “undruggable” — a smooth-surfaced protein that medicine could not get a hold of.

The first generation of KRAS drugs — Amgen's Lumakras, Bristol Myers Squibb's Krazati — reached the market between 2021 and 2022. They bound to the mutated protein only when it was in its inactive state, which limited how comprehensively they could shut down the cancer. Roughly a third of patients responded; resistance typically developed within months. Daraxonrasib binds the protein in its active state and switches it off there, which appears to be the difference. It is, by the trial's own measures, the most effective treatment yet developed for a disease that has refused to yield.

II. How the breakthrough was made

Revolution Medicines was founded in 2014 by a physician-scientist named Mark Goldsmith, with seed capital from Third Rock Ventures, one of the most influential biotech venture firms in the United States. For its first four years the company worked on a different target. The pivotal moment came in 2018, when Revolution acquired a smaller biotech called Warp Drive Bio. The acquisition brought with it a proprietary “tri-complex” chemistry platform — the technology that would later allow Revolution to bind RAS proteins in their active state. The platform did not exist inside Revolution before the acquisition. It came in through a buyout.

Also in 2018, Revolution signed a partnership with the French pharmaceutical giant Sanofi worth up to $550 million for development of an earlier-stage drug candidate. The partnership ran for four years. In late 2022, Sanofi walked away. Revolution went public in February 2020 at $17 per share, raising $238 million. In June 2025, the company closed a $2 billion financing arrangement with Royalty Pharma — the world's largest acquirer of pharmaceutical royalty streams — in exchange for future revenue rights on its drug portfolio. Revolution's stock surged on the day after the ASCO data, trading above $157. The company's market capitalisation now stands at approximately $31 billion. Wall Street rumours of buyout interest from Merck reportedly reached the $28-32 billion range earlier in 2026 before negotiations collapsed over price; the public market has now caught up to those figures on its own. AbbVie has been mentioned in the same conversations.

III. Who profits

The shareholders who stand to benefit most are not a single identifiable group. Revolution Medicines is owned, in declining order of concentration, by venture capital, hedge funds, mutual fund giants, the founders, and a long tail of retail investors.

Third Rock Ventures, which led the original founding round, held nineteen percent of the company at the 2020 IPO. The largest institutional shareholders today include Vanguard (around nine percent), Farallon Capital Management (around eight percent), Janus Henderson, Baker Bros. Advisors, BlackRock, Fidelity, Wellington Management, and State Street. Mark Goldsmith and the founding team retain insider equity. Royalty Pharma holds future royalty rights from its $2 billion deal. A portion of the upside flows, through mass index funds, into the retirement accounts of households that own diversified portfolios — though biotech equity ownership is itself concentrated among wealthier households rather than spread broadly. The outsize returns — the venture multiples, the concentrated hedge fund positions, the founder stakes, the structured royalty deal — flow to a much narrower group. The breakthrough, in financial terms, belongs to the people who put money in early and have stayed.

IV. What it will cost

Revolution Medicines has not announced a list price for daraxonrasib. The relevant precedents are the first-generation KRAS drugs already on the market. Amgen lists Lumakras at $17,900 per month. Bristol Myers Squibb lists Krazati at $19,750 per month. Both translate to roughly $215,000 to $237,000 per patient per year at U.S. list price, before any insurance negotiation or assistance programme.

Daraxonrasib is meaningfully more effective than either of its predecessors. There is no commercial reason to price it lower. Analysts have estimated the drug's overall market opportunity in pancreatic cancer alone at more than $10 billion. Roughly sixty thousand Americans a year are diagnosed with pancreatic cancers carrying the relevant mutations. The combination of patient volume and pricing power is what underwrites the $31 billion valuation.

U.S. list prices are typically the highest in the world for any patented drug. European, Canadian, Australian, and Japanese national health systems negotiate aggressively and routinely pay thirty to sixty percent less. Indian generic manufacturers, when patents permit, produce equivalents at one to three percent of the U.S. list price. The differential is a function of policy choice rather than chemistry. The United States, alone among wealthy countries, restricts the ability of its largest public payer — Medicare — to negotiate drug prices for most medications, a constraint partially modified by the Inflation Reduction Act of 2022 but still substantially in place.

V. The regulatory pathway

Revolution Medicines plans to file its New Drug Application using a Commissioner's National Priority Voucher. The voucher is the signature drug-approval initiative of the current FDA, launched in June 2025 by Commissioner Marty Makary. It collapses the standard ten-to-twelve-month review timeline to roughly one to two months, through enhanced communications, rolling review, and a multidisciplinary “tumour board” meeting structure. By early 2026, the FDA had issued eighteen such vouchers.

The official criteria for the voucher include breakthrough therapy status, response to unmet medical need, domestic manufacturing, and — explicitly — affordability. Commissioner Makary has stated that vouchers go to “a select group of products where the company has agreed to increase affordability, domesticate manufacturing as a national security issue, or address an unmet public health need.” The Department of Health and Human Services has cited “increasing medication affordability (with Most Favored Nation pricing)” as a stated priority of the programme. Whether Revolution Medicines has made any affordability commitment in exchange for its voucher has not been disclosed. The question is worth asking.

The voucher programme itself was developed in a regulatory environment shaped by sustained pharmaceutical industry lobbying. The industry trade groups PhRMA and BIO spent a combined $40 million-plus on federal lobbying in 2025 alone, with FDA review timelines among their stated priorities. Faster review benefits patients waiting for therapies; it also benefits manufacturers by extending the effective patent-protected revenue window. Both outcomes are real. Readers should understand which incentives are operating in the same direction.

VI. Who can access it

Some patients are already receiving daraxonrasib. On 30 April 2026 — two days after Revolution Medicines submitted the request — the FDA issued a “safe to proceed” letter authorising an Expanded Access Program for patients with previously treated metastatic pancreatic cancer. Under the programme, U.S.-licensed physicians can submit requests on behalf of eligible patients who cannot participate in a clinical trial. Approximately 900 patients are planned for enrollment. Some U.S. treating practices have confirmed they have already ordered and received daraxonrasib for their patients. The Expanded Access Program is not full FDA approval — it is a controlled pathway for investigational drugs, with the company retaining discretion over individual cases. But for a small number of American patients with the right diagnosis, the right physician, and the right institutional connections, daraxonrasib is no longer a hypothetical future treatment.

In the United States, daraxonrasib will reach patients with comprehensive private insurance or Medicare Part D Tier 5 coverage relatively quickly, though typically with prior-authorisation requirements and significant coinsurance. Manufacturer patient-assistance programmes will reach some of the uninsured and underinsured. Most insured American patients will not pay full list price; many will pay copays in the low thousands of dollars.

In Europe, national health systems negotiate prices through bodies like NICE in the United Kingdom and equivalent agencies in Germany, France, and elsewhere. Routine European access typically lags U.S. approval by one to three years. In Canada, Australia, and other wealthy systems with strong central negotiating power, similar delays apply.

For the great majority of the world — the low- and middle-income countries where pancreatic cancer kills people just as surely as it does in Houston or Lyon — the drug will be effectively unavailable. Generic versions are roughly a decade away. The patent will protect Revolution's pricing power until then.

VII. Two truths, held together

A genuine medical breakthrough has occurred against one of the most lethal cancers in human medicine. It will save lives. It is the product of a specific structure — venture capital, platform acquisitions, late-stage trials, public listing, sophisticated financing — that does work and produces results. The structure is not an accident; it is what currently delivers transformative drugs in the United States.

The same structure determines who receives the drug. Tens of thousands of patients in wealthy countries with adequate insurance will live longer because of it. Tens of thousands more, in those same countries and in poorer ones, will not — some because their insurance cannot bear the cost, more because they live in countries whose health systems cannot. The breakthrough is real. So is the bill. The system that produced this drug is also the system that determines who receives it. Both deserve scrutiny.